Publications by authors named "C Baldessari"
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study.
Clin Genitourin Cancer
November 2024
Article Synopsis
- The IMDC score is crucial for predicting outcomes and guiding treatment in patients with metastatic renal cell carcinoma (mRCC), especially when starting therapy with nivolumab.
- A multicenter study analyzed 492 mRCC patients to see how changes in IMDC categories affected their overall survival (OS) and progression-free survival (PFS) after starting nivolumab.
- Results indicated that patients maintaining or improving their IMDC category had better survival outcomes compared to those whose condition worsened, highlighting the importance of IMDC monitoring in mRCC treatment.
The standard of care for advanced or metastatic urothelial carcinoma (mUC) was historically identified with platinum-based chemotherapy. Thanks to the advances in biological and genetic knowledge and technologies, new therapeutic agents have emerged in this setting recently: the immune checkpoint inhibitors and the fibroblast growth factor receptor inhibitors as the target therapy for patients harboring alterations in the fibroblast growth factor receptor (FGFR) pathway. However, chasing a tumor's tendency to recur and progress, a new class of agents has more recently entered the scene, with promising results.
View Article and Find Full Text PDFMore than 20% of metastatic prostate cancer carries genomic defects involving DNA damage repair pathways, mainly in homologous recombination repair-related genes. The recent approval of olaparib has paved the way to precision medicine for the treatment of metastatic prostate cancer with PARP inhibitors in this subset of patients, especially in the case of or pathogenic/likely pathogenic variants. In face of this new therapeutic opportunity, many issues remain unsolved.
View Article and Find Full Text PDFIntroduction: Vaginal cancer is a rare gynecologic malignancy. While in a localized disease, concurrent chemoradiation grants local control and better overall survival, in a metastatic setting, the management options are very limited. Furthermore, recurrent cervical, vulvar, and vaginal carcinomas notoriously develop resistance to treatment, and consequently, their prognosis is still poor.
View Article and Find Full Text PDFArticle Synopsis
- - Endometrial cancer (EC) rates are rising, especially among young women, with a small percentage being hereditary, primarily linked to Lynch syndrome.
- - Traditional EC classification is based on histopathology but is now considered inadequate due to the complexity of molecular differences; TCGA introduced a new four-group molecular classification in 2013 that offers better prognostic insights.
- - The manuscript reviews the latest EC molecular characteristics and hereditary links, emphasizing their importance as prognostic and predictive markers for clinical practice.